Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:18:22.539Z.
Calculation as of: 2026-10-06T16:18:22.539Z.
Quote observation: 2026-10-06T16:14:44.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e1640542559587d997c0d8eaeaaf8c892bebef217736e9d4e66575bab6404537
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pliant Therapeutics, Inc. (PLRX) | $63.83M | N/A | N/A | N/A | N/A |
| Alps Group Inc (ALPS)vs › | $63.23M | N/A | N/A | N/A | N/A |
| InterCure Ltd. (INCR)vs › | $63.02M | N/A | 0.60 | 0.60 | 0.60 |
| Heron Therapeutics, Inc. (HRTX)vs › | $63.50M | N/A | N/A | N/A | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $64.96M | N/A | N/A | N/A | N/A |
| Cingulate Inc. (CING)vs › | $65.80M | N/A | N/A | N/A | N/A |
| RenovoRx, Inc. (RNXT)vs › | $66.30M | N/A | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.34M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $60.95M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $60.78M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute